Efficacy of living donor liver transplantation for patients with methylmalonic acidemia.

Authors:
A Fukuda
A Fukuda
Tokyo Dental College
Japan

Am J Transplant 2007 Dec 1;7(12):2782-7. Epub 2007 Oct 1.

Department of Transplant Surgery, National Center for Child Health and Development, Tokyo, Japan.

Application of liver transplantation to methylmalonic acidemia (MMAemia) is controversial because MMAemia is caused by a systemic defect of methylmalonyl-CoA mutase. The clinical courses of seven pediatric patients with MMAemia undergoing living donor liver transplantation (LDLT) were reviewed. Serum and urinary methylmalonic acid (MMA) levels were found to be significantly decreased after LDLT, whereas serum and urinary MMA levels did not return to normal in any patient. One patient died of sepsis 44 days after LDLT. The other six patients are currently doing well. All patients had preoperative history of acute metabolic decompensation and/or metabolic stroke. However, no episode of acute metabolic decompensation or metabolic stroke was observed postoperatively in any surviving patients. In the preoperative period, all patients showed lethargy and cognitive deficit, both of which were eradicated after LDLT in all surviving patients. Preoperatively, all patients were subjected to dietary protein intake restriction and tube feeding, and were administered several metabolism-correcting medications. The metabolism-correcting medications being administered remained mostly unchanged after LDLT, whereas protein restriction was liberalized and tube feeding became unnecessary in all surviving patients. In addition, physical and neurodevelopmental growth delay remained in all surviving patients during the observation period, which ranged from 4 to 21 months with a median of 10.5 months.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-6143.2007.01986.xDOI Listing
December 2007
5 Reads

Publication Analysis

Top Keywords

surviving patients
16
liver transplantation
12
patients
10
mma levels
8
serum urinary
8
patients preoperative
8
metabolic decompensation
8
metabolism-correcting medications
8
tube feeding
8
metabolic stroke
8
methylmalonic acidemia
8
acute metabolic
8
donor liver
8
living donor
8
ldlt
5
well patients
4
currently well
4
patients currently
4
medications metabolism-correcting
4
efficacy living
4

Similar Publications

Current role of liver transplantation for methylmalonic acidemia: a review of the literature.

Pediatr Transplant 2006 Dec;10(8):943-7

Department of Transplant Surgery, National Center for Child Health and Development, Tokyo, Japan.

To evaluate the current role of liver transplantation (LT) for methylmalonic acidemia (MMA), we reviewed the literature on outcomes of this treatment, and describe three of our own cases of living-donor liver transplantation (LDLT). The total number of LT cases identified was 18. Transplantation mode was deceased donor LT in 12, including five combined liver-kidney transplantations (CLKT) from deceased donors, and LDLT in six. Read More

View Article
December 2006

Living donor liver transplantation for noncirrhotic inheritable metabolic liver diseases: impact of the use of heterozygous donors.

Transplantation 2005 Sep;80(5):623-8

Organ Transplant Unit, Kyoto University Hospital, Japan.

Background: In living donor liver transplantation (LDLT), the liver donor is almost always a blood relative; therefore, the donor is sometimes a heterozygous carrier of inheritable diseases. The use of such carriers as donors has not been validated. The aim of the present study was to evaluate the outcome of LDLT for noncirrhotic inheritable metabolic liver disease (NCIMLD) to clarify the effects of using a heterozygous carrier as a donor. Read More

View Article
September 2005

Stabilization of blood methylmalonic acid level in methylmalonic acidemia after liver transplantation.

Pediatr Transplant 2010 May 14;14(3):337-41. Epub 2009 Aug 14.

Department of Medical Genetics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Methylmalonic acidemia with complete mutase deficiency (mut(0) type) is an inborn error of metabolism with high mortality and morbidity. LT has been suggested to be a solution to this disease, but elevation of urinary and blood MMA was still observed after LT. In this study, we measured dry blood spot MMA and its precursor propionyl-carnitine (C3-carnitine) for mut(0) patients. Read More

View Article
May 2010

Management of methylmalonic acidaemia by combined liver-kidney transplantation.

J Inherit Metab Dis 2005 ;28(4):517-24

Pediatric Nephrology, Stanford University, California 94305-5208, USA.

Methylmalonic acidaemia (MMA) is a rare autosomal recessive inborn error of metabolism that typically presents in infancy with recurrent episodes of metabolic acidosis, developmental delay and failure to thrive. The disease course is complicated by the development of chronic tubulointerstitial nephritis progressing to end-stage renal disease in adolescence. We describe two adolescents with cobalamin-nonresponsive MMA (mut0) who developed polyuria, chronic tubulointerstitial nephritis, dystonia but normal synthetic liver function. Read More

View Article
September 2005